依达拉奉治疗急性脑梗死临床研究

Therapeutic effect of Edaravone on acute cerebral infarction

目的观察依达拉奉治疗急性脑梗死的临床疗效。方法选择发病48h内的急性脑梗死患者96例,随机分为依达拉奉治疗组49例和对照组47例。治疗组应用依达拉奉静脉给药,剂量为30mg,2次/d,共14d,余治疗与对照组相同。治疗前后对患者进行欧洲卒中评分(ESS)、日常生活能力(ADL)、APACHEⅡ评分及C-反应蛋白(CRP)的测定。结果在治疗7d后,治疗组的各项指标就较治疗前有显著差异,其中ESS和ADL有显著升高(P<0·01,P<0·05),APACHEⅡ和CRP有显著下降(P<0·05),治疗组的ESS和APACHEⅡ与对照组比较有显著差异(P<0·05),对照组的各项指标较治疗前无明显变化;在治疗14d后,对照组的各项指标才较治疗前出现显著差异,而同期治疗组的各项指标与对照组比较均有显著差异。治疗组无严重不良反应。结论依达拉奉能够安全有效的治疗急性脑梗死。

Objective To investigate the therapeutic effect of Edaravone on acute cerebral infarction. Methods 96 patients with acute cerebra1 infarction were randomly divided into two groups：treatment group（49 cases）and control group（47 cases）.The therapies of the two groups were similar except that treatment group was treated with Edaravone at a dose of 30 mg,twice a day,for 14 days.The European Stroke Scale（ESS）,activities of daily living（ADL）,APACHE Ⅱ scores and C-reactive protein（CRP） level were evaluated before and after treatment. Results After 7 days treatment,the scores of ESS and ADL were significantly increased （P001,P005）and the APACHE Ⅱ scores and CRP level were significantly decreased （P005）in treatment group than before treatment, and there were significant difference of ESS and APACHE Ⅱ scores between treatment group and control group （P005）,but there were no significant difference of all the four variables in control group.After 14th day treatment,there were significant difference of all the four variables in control group than before treatment, and there were significant difference of all the four variables between two groups. Conclusion Edaravone is an effective and safe medicine in the treatment of acute cerebra1 infarction.